Cell Isolation GNPs were obtained from cerebella of 7-day-old WT mice, and tumor cells were obtained from 10-to 25-week-old Ptc and Math1-GFP/Ptc +/-mice displaying physical and behavioral signs of medulloblastoma. Cells were isolated as previously described (Oliver et al., 2005) . Briefly, tumor tissue was digested in a solution containing 10 U/ml papain (Worthington, Lakewood, NJ) and 250 U/ml DNase (Sigma), and triturated to obtain a cell suspension. This suspension was centrifuged through a step gradient of 35% and 65% Percoll (Amersham Biosciences), and cells were harvested from the 35%-65% interface. Cells were resuspended in serum-free medium consisting of Neurobasal plus B27 supplement, sodium pyruvate, Lglutamine and penicillin/streptomycin (all from Invitrogen). Cells used for RNA isolation were centrifuged and flash frozen in liquid nitrogen. For proliferation assays cells were plated on poly-D-lysine (PDL)-coated tissue culture vessels and incubated in serum-free culture medium. To detect expression of surface markers by fluorescence-activated cell sorting (FACS), cells were resuspended in FACS buffer (Dulbecco's PBS + 5% FCS).
microscopy or stained for viability using a two-colored cell viability assay (Live/Dead Assay Kit, Invitrogen).
In Vivo Staining for CD15
Since our preliminary studies suggested that the CD15 epitope was sensitive to fixation and/or freezing, we labeled CD15 + cells in vivo by injecting anti-CD15 secreting hybridoma cells into the forebrain, as previously described (Barres et al., 1992; Wechsler-Reya and Scott, 1999) . Briefly, anti-CD15-secreting hybridoma cells (clone MMA, Catalog #HB-78) or isotype control hybridoma cells (clone 10E5, Catalog #HB-8513, both from American Type Culture Collection) were resuspended in serum-free medium containing 500 U/ml DNase at a density of 3 × 10 5 cells/μl. Cells were taken up in a 10 μl Hamilton syringe, and injected into Math1-GFP mice at P4 or into tumor bearing Ptc +/-or Math1-GFP/Ptc +/-mice at the first sign of symptoms. Cells were injected subpially, above the left frontal lobe, with 3 μl (approximately 1 × 10 6 cells). Three days after injection, mice were sacrificed, and cerebella were removed and fixed in 4% PFA. Cerebella were then sunk in 25% sucrose, frozen in O.C.T. and sectioned using a cryostat. Sections were post fixed with 4% PFA, blocked in PBS containing 2% BSA, 10% normal goat serum and 0.1% Triton X-100, and stained for 2 hours with Alexa Fluor-568-conguated goatanti-mouse IgM (Invitrogen), and mounted with Fluoromount G. Samples were imaged and processed as described above.
Proliferation Assays
Tumor cells isolated as described above and resuspended in serum-free medium (Neurobasal + supplements) and transferred to PDL-coated 96-well plates, at a density of 2 x 10 5 cells/well. Cells were grown for 48h and pulsed with tritiated thymidine (methyl-[ 3 H]-Td, Amersham) and cultured for 14 hours. Following culture, cells were harvested onto filters using a Mach IIIM Manual Harvester 96 (Tomtec) and the amount of incorporated radioactivity was quantitated by liquid scintillation spectrophotometry using a Wallac MicroBeta microplate scintillation counter (Perkin Elmer).
RNA Isolation and Real-Time RT-PCR
To isolate total cytoplasmic RNA from GNPs and tumor cells, cell pellets were snap-frozen and RNA was isolated using the RNAqueous-Micro kit (Ambion), as described by the manufacturer. RNA was treated with DNase 1 (DNA-free, Ambion) to remove genomic DNA. RNA concentration was determined using the RiboGreen fluorescent dye (Molecular Probes) with a TD-700 fluorometer (Turner BioSystems). For real-time RT-PCR analysis, first-strand cDNA was synthesized using equivalent amounts of total RNA (0.1-1 µg) in a 20 µl reverse transcriptase reaction mixture (Invitrogen). Real-time PCR reactions were performed in triplicate using a 25 µl mixture containing iQ SYBR Green Supermix (BioRad), water, primers and 1 µl of cDNA. Gene-specific primers were used for Nmyc, cyclin D1, Gli1, Ptc-1 (exons 2-3 and 7-9) Tag-1, Ccnb1, Tle2, NeuroD1, Survivin, Hrk, Dcx and Notch2 ; sequences for these are available upon request. Real-time quantitation was performed using the BIO-RAD iCycler iQ system (BioRad). Serial tenfold dilutions of cDNA were used as a reference for the standard curve calculation. Raw data were normalized based on expression of actin. In addition to real-time analysis, expression of Ptc-1 exons 2-3 and 7-9 was also analyzed by conventional RT-PCR. Products were separated by electrophoresis on a 2% agarose gel and visualized after staining with ethidium bromide.
Microarray Preprocessing and CD15
+ Signature Development A CD15 + signature was developed by comparing microarray detected gene expression differences between tumor cells sorted for the absence of CD15 (CD15 -, n =6) or presence of CD15 (CD15 + , n =6) and using Bayesian methodologies for supervised learning as previously described (Bild et al., 2005; Huang et al., 2003; West et al., 2001 Affymetrix data were pre-processed by using the standard methodology RMA Irizarry et al., 2003) , making a log2-transformation, and applying a filter to exclude the 10% of probe sets with the lowest variation in expression resulting in 40591 remaining features from the total number of 45101 features on the Mouse Genome 430 Plus 2 arrays. To identify differentially expressed genes, Student's t-tests were applied to the mean expression of samples after at least 12 hours of androgen exposure as compared to the mean expression of samples without androgen exposure. To control for the false discovery rate (FDR) of multiple tests, the Benjamini-Hochberg step-up procedure was applied to the nominal p-values (Benjamini and Hochberg, 1995) . The method for building a CD15 + signature first identified a set of genes with the strongest levels of differential expression by CD15 expression status, as determined by t-tests (top 300 genes). A summary measure for the expression profile of the gene set, termed 'metagene', was derived from the top principle component of a singular value decomposition (SVD) (i.e. the linear combination of expression values that captures the most variance between phenotypes). A Bayesian probit regression model was used to build a predictive signature for the phenotypic differences. The determination of internal accuracy of the predictive signatures was assessed through proper leave-one-out cross-validation (see below), whereby the feature selection (i.e. metagene membership) is repeated for each iteration, and accuracy is determined according to a predictive probability ≥ 0.50 for each removed sample.
Proper Leave-One-Out Cross-Validation
Proper leave-one-out cross-validation is a method of analysis that tests for internal consistency of models derived from gene expression data. In leave-one-out cross-validation, starting with an original set of two classes or groups (e.g. a group of CD15 + samples and a group of CD15 -samples), one sample is removed and the remaining samples are used to develop a predictive model based on the differences between the two classes. The model generated is then applied to the left out sample to "guess" the identity of the sample. This is done, in turn, with each sample in the dataset. The accuracy and internal consistency of the model is judged based upon how well the "guessed" identity of the left out samples agrees with the known identities. The term "proper" refers to a method of leave-one-out cross-validation where the model is re-generated after each sample is left out. Earlier, less valid, forms of leave-one-out cross-validation generated a model using all samples, then left out single samples and applied the model generated on all samples to the left-out sample. This is less valid because information from the left-out sample was used to generate the model. This is a common method applied to models generated from complex data (for example, see (Singh et al., 2002) ).
Development of a CD15
+ Signature Mouse medulloblastomas were found to have a population of CD15 + cells that could propagate tumors and a CD15 -population that could not. Using recently developed computational methods we utilized differentially expressed genes to create a "signature" of the CD15 + tumor-propagating cell population. For all analyses, the CD15 + signature was set at 300 genes and 1 metagene as this approximates the number of genes used in previously validated signatures (Bild et al., 2005; Potti et al., 2006) .
Validation of the CD15
+ Signature The CD15
+ signature was applied to an additional set of CD15 sorted medulloblastoma cells to validate that the CD15 + signature could differentiate between two populations in an independent dataset. The files to which the CD15 + signature was applied were as follows: During the validation process, the original training samples used to develop the CD15 + signature (n =12) were merged with the test samples (n =10) using Filemerger (http://tenero.duhs.duke.edu/genearray/perl/filemerger.pl) after expression values for each set were determined separately using RMA. Again, the same 10% filter was performed to exclude genes with minimal variation within the training samples. The CD15 + signature was re-derived on the training samples and applied to each of the 10 test samples. This resulted in the assignment for each sample of a probability from 0 to 1 reflecting the similarity of the sample to the CD15 + cells (perfect match would result in a probability of 1.0) compared to the CD15 -cells (perfect match would result in a probability of 0.0). The results of each test sample is provided in the Application of the CD15 + Signature The CD15
+ was subsequently applied to two previously published datasets comprised of microarray data from human medulloblastoma tumors. As the CD15 + signature was derived from murine cells on the Mouse microarrays, cross species and cross platform probe matching had to be performed. To accomplish this, an online resource developed at Duke was used called Chip Comparer (http://tenero.duhs.duke.edu/genearray/perl/chip/chipcomparer.pl). This allows users to find perfect match probes between previously annotated arrays. The Mouse Genome 430 Plus 2 array was used as microarray A ("Mm:Mouse430_2") and the Affymetrix HuGene FL ("Hs:HuGeneFL") or the Affymetrix U133A version 2("Hs:HG_U133A_2") were used for the Pomeroy et al. and Thompson et al datasets, respectively, using primary UniGene cluster ID available from Affymetrix annotation file only ("primary locusID") and keeping multiple matches between the two platforms in separate rows ("in separate rows"). These ChipCompare files were then used together with the RMA processed files for the training samples and, separately each of the medulloblastoma datasets, to create single merged files using File Merger. All duplicate probes from either platform were removed after the files were merged and the remaining probe sets (n = 4748 for Pomeroy et al and n = 10745 for Thompson et al) were filtered to remove probes with minimal variation (probes with the lowest 10% Standard Deviation across training samples ) (n = 4276 remaining for Pomeroy et al and n = 9671 for Thompson et al). These files were then used to re-derive the CD15 + signature in the training samples from the mouse and apply the signature to each of the samples from both datasets as described above. Importantly, the same parameters were used to derive the signature: 300 genes and 1 metagene. Figure S1 . Screening for Markers that Enrich for Tumor-Propagating Cells (A) Antibodies directed against the indicated cell surface antigens were used to stain tumor cells from Ptc +/-mice, and the percentage of positive and negative cells was determined. The majority of markers were not consistently expressed and were excluded from further analysis. Three markers -HNK1, GD3 and CD15 -were found in all tumors examined, and were tested to determine if they could be used to enrich for tumor-propagating cells by stereotaxic implantation into the cerebellum of SCID-beige mice.
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(B) Tumors developed with similar frequency in animals that received HNK1 + and HNK1-cells, indicating that this marker could not be used for enrichment. (B) Leave-one-out cross-validation demonstrates that a robust model can be developed using these samples. Samples are plotted with confidence intervals based upon the predicted probability of the sample having a CD15 + signature (y-axis) and the metagene score from binary regression during leave-one-out cross-validation. Blue numbers (1-6) represent CD15 -samples, red numbers (7-12) represent CD15 + samples. Numbers are placed at the probability value, and vertical lines indicate 95% confidence intervals. Dashed horizontal line indicates 50% probability.
(C) Probability of being scored as CD15 + based on gene signature (y-axis) for independent samples sorted based upon CD15 staining (Blue circles, CD15 + cells; red circles, CD15 -cells; horizontal lines, mean probability for CD15 + and CD15 -samples). 
